Touch Medical Media Services's video: Jorge E Cortes ASCO20: 5-Year Analysis of the Phase II PACE Trial of Ponatinib in Ph leukemia

Jorge E Cortes, MD Anderson Cancer Center, discusses the 5-year analysis presented at ASCO20 of arterial occlusive events in the ponatinib phase II PACE trial (NCT01207440) in patients with Ph+ leukemia. Questions 1. How has ponatinib fitted into the treatment paradigm for haematological malignancies? (0:06) 2. Could you tell us about the objectives and patient population of the PACE study? (1:57) 3. What were the major efficacy and safety findings from this study? (3:40) Speaker disclosure: Jorge E Cortes has received grant support from BMS, Novartis, Pfizer, Takeda and Sun Pharma. He is a consultant for Novartis, Pfizer and Takeda. Support: Interview and filming supported by Touch Medical Media. Commissioned in liaison with W2O Group. Filmed in coverage of the 2020 ASCO Virtual Scientific Program.